YAP1 and sarcoma: Our observations in a large cohort of tumors (n = 486) comprising 10 different sarcoma subtypes document highest YAP1 and/or TAZ nuclear levels in myxoid liposarcomas (MLS), synovial sarcomas (SySa), malignant peripheral nerve sheath tumors (MPNST) and angiosarcomas (AS), implying a pathogenic role of YAP1/TAZ activity.